we know pricing pressure has been a key challenge for a lot of pharma firms. they come on cnbc often and tell us that's one of the main things eating into their profit. a couple of hot bios is alexion. another one is biomarin. you guys will be chatting with the ceo. i was talking to j.j. a little while ago. he said there's a lot of untapped opportunity in the rare disease space. i'll let you guys take it from there. >> seema, thank you very much for the set-up there. biomarin pharmaceutical is one of the dominant players in this space. shares up nearly 42% over the past six months. what is the nothing know sis for rare disease treatments? let's bring in j.j., the biomarin pharmaceuticals ceo. this is a niche area. does it mean less competition or do you feel that some of the big boys, like pfizer, increasingly looking at the rare disease space as well? j.j., can you hear us? >> yes, i can. sorry. it's a pleasure to be here. >> the question is whether or not you, therefore, have less competition because it's a niche area or do you feel that the competition is h

seema mody is at a pharma meeting in orlando. this is exciting news. >> very exciting. we're talking about it being a $3 billion drug by 2020. that's at least what some analysts are estimating. a sweet victory for any pharma firm, but even more so for vivus as it's been a long road. the fda panel voting 20 to 2 in favor of the weight loss drug setting the stage for a potential comeback. it was plagued by questions since first submitted to the agency in 2010. it was rejected by the fda due to some safety concerns. the company went back to the drawing board and now in 2012 the fda panel seems to be convinced that the benefits of the drug outweigh the risks. now, the ceo telling cnbc that he's very optimistic that the drug would be approved and he's targeting april 17th as the day of approval. now, mandy, if this drug is approved, vivus could get access to the market that could improve. saying a new weight loss drug is need today treat this growing epidem epidemic, according to the cdc nearly 33% of americans are obese. 67% are overweight. and by 2030, 51% of adults in ame

. >> i'm seema mody reporting live from the pharma conference. coming up, we'll take a deep dive into the generic drug market, who the winners and losers are, and how investors are trading the space. here's another question. will the usda guidelines slow it down. here's highlights from our guests on cnbc today. >> it's become clear that hiring has declined. the real question is what it means for the apparels, how quickly will hiring pick up. >> this time of the year, over the past ten years we've seen an uptick in prices as the market switches from winter grade gasoline to summer grade gasoline. cleaner burning gasoline is better for the environment, costs more to produce. at the same time consumption and demand increases as the days get longer. >> in the euro, you haven't seen anyone trying to weaken the euro. i think they're happy to see it go lower if it does. i think it helps the situation over there. and desperately in need of some help. >> romney needs to win michigan, period. this is a neck-and-neck race. i think he's going to throw everyt

we go live to orlando at the generic pharma conference with more.good morning, carl. biotech investors salivate over the thought of an instant double. that is certainly a topic of discussion here at the 2012 annual meeting for international drug, generic drug makers. the lure of the biotech sector, the overnight riches some of the investors make, the fda has the power in terms of driving a stock higher and lower. the news that came out on vivus' q next is driving shares on other companies. take a look at arena, the street making the assumption that the fda may be lightning up on other obesity fighters. not to be a debby downer you got to keep in mind qnexa doesn't mean the fda will agree. all the supporting data can be there and even then the fda can still ask for additional data or for further clinical trials. so, carl, that's what makes this sector so volatile, so exciting, is the fact that you just never know what you're going to get. it's kind of like watching a bad hollywood romance. you never know what you're going to get. >> in so many ways.

the big question is, will these pharma players be financially impacted?e to said they're not changing their ratings or estimates in response to this news. many of them already expect a deceleration in sales given the availability of generic options. it's still considered a headwind being monitored very closely. patients will naturally question if the benefits of being on a statten outweigh the risks. tyler. >> now, seema, i at least know where my memory went. gold having worst day in two montds. ben bernanke doing little to boost the hopes of qe during his testimony on ch. that would be capitol hill. prices ready to close right now. sharon epperson tracking the action at the nymex. >> tyler, we're closing at the lows of the session. we've seen gold now dip to $1705 an ounce for the intraday low. and we're down about $80 in the price here of course bernanke's comments the lack of any really stimulus talk that's certainly what has precipitated this decline but what exacerbated the decline is the fact that gold prices tried time and again to retest those nov

that's why, you know, big pharma spent $150 million lobbying for this bill. they showed up at the white house, billy tosen went and met with the president and came out with agreements to campaign for this bill because they know there's a lot in this bill now, every insurance plan in america has to coffer their prescription drugs, there's going to be a whole bunch of new expansions in medicare for them, brand name drugs covered under the doughnut hole where they were going to generics. so they came out ahead. big insurance, you know, they dropped the public option x they got a mandate that people have to buy their product. it's a $70 billion a year bailout for the insurance industry. now, the small and medium insurance companies can't comply, they're going to go out of business, but that's great for the big insurance companies who are going to control every last little bit of the market. i think the ama lobbied in favor of this bill because they think that's going to mean that their doctors are going to get special treatment under this. they're going to get th

their cheap processed food by the sec human founded and online organic store trying to help small pharma survive and at the same time improve the quality of life while food conscious customers just like him. initially we simply wanted healthy stuff for our families and friends now we hand pick each person involved in the production of meat or bread that we sell so that we know where the food has come from and the business is growing. some going as far as saying russia with its plenty of land could eventually become an organic food basket for the whole world a very few europe in one hundred fourteen russia fed half of the world and we could easily get back to that but the state needs to start investing in agriculture. and while city dwellers are only starting to go back to their roots milledge is in russia's most organic far away corners are probably unaware of the treasures they could offer the russian klondike to be discovered. r.t. scary. our web site r t dot com is the place where you can find all of the latest news and analysis including this. two iranian warships have a sailed throu

what is next for the generic pharma leader? into your business, you are a ceo that does a lot of business around the world. you just heard somebody from the white house effectively say that they want to change tax laws as regards to taxation of profits and cash overseas. right? >> yes. >> i countered that that might encourage companies to move overseas. he did not seem to buy that argument. you are a ceo, do you buy that argument? >> look, i absolutely agree that the united states needs to look to do something to encourage corporate growth in the united states. i think we have the second largest tax rate in the world. so i absolutely am for let's look at lowering that. i think there are a ton of loopholes that need cut out. but i'm not as familiar with the plan they came out with today that if it actually does that. it doesn't sound like you're convinced. >> we don't know all the details is my point. and we've talked about this, let's say the fda requires inspection every two years of the facilities in the u.s., which is a good

have done extensively, the manufacturing capacity needs to be increased and a number of the major pharma companies are in the process of doing that, they are just behind the demand. >> i think the government has been behind. >> thank you, madam secretary, appreciate you being here. i have two areas i want to discuss with you. one in your testimony you talked about saving seven dollars out of every dollar you put in fraud prevention, you came up with a number of $4 billion. o outside estimates improper payments over $59 billion in fraud and medicaid and medicare, close to $100 billion a year. we're at 4%. my question is you all signed a contract for $77 million on a cost basis with three firms never done what you're asking them to do. and at the same time another firm, who has done this for 70% of all the insurance companies in this country, in terms of predictive payment, and whether to pay or look, offered to do this for free for the government. i understand the government can't take free services, but it is concerning to me that we would go with three contractors who have no experience

oklahoma democrats also voted against it and also got donations from big pharma one oklahoma rep saidw he would be able to look social workers, or cops in the eye, he said: and that was doug cox a republican and he deserves applause for telling it like it is. but his colleague planned parenthood. anna talked to a conservative and it got a little contentious. drama, when we return. the newest voice in cable news is on the new news network. >>it is an independent progressive voice and i love that. >>jennifer granholm joins current tv. a former two term governor. >>people like somebody who's got a spine. >>determined to find solutions... >>we need government to ensure that people have freedom. >>driven to find the truth... >>what's really going on? >>fearless, independent and above all, politically direct. hey don't worry, e-trade's got a totally new investing dashboard. everything's on one page. i'm watching you. oh yeah? well i'm watching you, watching him. [ male announcer ] try the new 360 investing dashboard at e-trade. [ male announcer ] this is lawn ranger -- eden prairie, minneso

state that are in league with the government now the wall street banking complex you have the big pharma medical complex but not talked about much is the military industrial complex these are the people who profit wildly profit from war they love a war that promote war there's also a security aspect to this because of the department of homeland security but war is about the most profitable thing for any of the institutions connected to the government and these people they want to increase their profits and they do so by promoting war and instigating wars they work with the government we see now you know the run up against syria and the run up against especially iran they'd like all these countries destroyed and turned into and to new colonies or to dependencies and i think other countries are. head of this pakistan even saudi arabia if we look at some of the plans that have been discussed to totally take over the middle east all and have the us empire run it. it's a very alarming thing it's all too real i would argue it was it had been all too real by the time i was in our gave a speech

why pharma need to now with our top story and the e.u. is preparing to further tougher toughen sanctions on syria in a bid to crank up pressure on the country's regime this is and came after russia and china vetoed the veto the latest draft u.n. resolution on syria moscow and beijing say the wording took sides of the syrian conflict so we blame the government for violence without mentioning armed extremist groups in syria opposition leaders claim at least fifty people have been killed in a fresh wave of attacks by the army on the city of homs the government denies the assault and amateur footage showing the alleged shelling cannot be verified sara furth reports an absence of credibility and video evidence from syria raises questions as to exactly what is happening in the country. each and social networking sites for the past ten months being one of the activists he means is offering the world glimpses of the violence is a tool in three syrian activists who support how we got the big deal of course and we've just seen pictures which the b.

making the government however in the government special interest the banks military industrial complex pharma medical complex all the big interest groups they of course do better but the average people get stepped on well and lou more broadly we've seen the west plunder other countries we've seen western countries use of financial turmoil to force for example privatization so we've seen it more in developing countries than in the developing world now that the west is where all of that debt is and we see western nations indebted our way saying the west turn that model onto itself. boy that would not be great i mean sell off the national parks and be a great thing sell off federal government and the united states owns you know most of california most of nevada most of many states we have sell all that land to productive private use and the government owns just vast resources that it has no business owning even if one believes in a government and so we have privatization is absolutely the way not typically of course the way it's happened in developing countries it's sort of a fascist privatizati

oklahoma democrats also voted against it and also got donations from big pharma one oklahoma rep saidhe would be able to look social workers, or cops in the eye, he said: and that was doug cox a republican and he deserves applause for telling it like it is. but his colleague planned parenthood. anna talked to a conservative and it got a little contentious. drama, when we return. >>the blood is in the water and the sharks are bipartisan. >>you got a bone to pick with that? hey don't worry, e-trade's got a totally new investing dashboard. everything's on one page. i'm watching you. oh yeah? well i'm watching you, watching him. [ male announcer ] try the new 360 investing dashboard at e-trade. [ male announcer ] this is lawn ranger -- eden prairie, minnesota. in here, the landscaping business grows with snow. to keep big winter jobs on track at&t provided a mobile solution that lets everyone from field workers to accounting, initiate, bill and track work in real time. you can't live under a dome in minnesota that's why there's guys like me. [ male announcer ] it's a network of possibilit

oklahoma democrats also voted against it and also got donations from big pharma one oklahoma rep saidhe would be able to look social workers, or cops in the eye, he said: and that was doug cox a republican and he deserves applause for telling it like it is. but his colleague it's a bit like asking if they want a big hat... ...'scuse me... ...or a big steak... ...or big hair... i think we have our answer. geico. fifteen minutes could save you fifteen percent or more on car insurance. the newest voice in cable news is on the new news network. >>it is an independent progressive voice and i love that. >>jennifer granholm joins current tv. a former two term governor. >>people like somebody who's got a spine. >>determined to find solutions... >>we need government to ensure that people have freedom. >>driven to find the truth... >>what's really going on? >>fearless, independent and above all, politically direct. [ male announcer ] this is lawn ranger -- eden prairie, minnesota. in here, the landscaping business grows with snow. to keep big winter jobs on track at&t provided a mobile solution

a company like inventive can provide clinical work for big pharma. it can provide sales force supplements for those companies when they want to detail a new product, or reintroduce an existing product. and it can provide a whole set of services, more cost effectively, but also better than some of their clients can. and therefore, for us, we're looking at both a growth trend for that market as well as being able to create one of the more effective competitors in that faster growing market. >> do you see opportunity right now in technology? for example, would you buy into facebook? >> facebook is a phenomenal company. i don't think you can say facebook is doing great, and therefore, everything in technology is worth what facebook is worth. but we have been an investor in information services. and related media plays for very long period of time. in fact, we were probably one of the earliest buyout firms to invest in technology companies, when we bought the tro credit and information business back in the '90s when we did the learning company, which is a

sort of soothing rise of drugs, enormous and giving them to toddlers which is quite a part of big pharma's agenda. so finally you get some cross and that is what they have done. i don't think orwell is necessary. just part of the hysteria the united states has as it loses its moorings. what kind of clout it has but frankly i don't agree with chris hedges of the ruling class is running scared. they sleep very well and they know they are going to keep -- that 1% -- more than 90% of its wealth. that is where we are. to me it is a ghastly sort of vision. it is a grim thing. try talking to americans about anything serious. they change the subject. they can't handle it. >> what do you think about the lack of empathy and message you get from the media is controlled or script or selected what you are going to see on tv and what you are not going to see? how do you think that all plays in? >> the or original title of this book was capitalism and its discontent. if i went with that title i would sell six books nationwide. maybe he was right. i liked it because of the freudian overtones. the reason i

these are both high-quality companies and we actually did a couple of pieces about big pharma and youdend boosts. merck just gave you one. j & j can certainly give you more. i don't think you can go wrong with either one. may i say that merck is more undervalued? they like j & j because it has over the counter products. i think merck is cheaper and they'll unlock more value and i do like a 4.41 yield more than a 3.5. i want to go to cosmee in illinois. >> caller: hey, jim, boo-yah! >> boo-yah! >> caller: i'm looking at the dog of the dow, intel. since last year the stock was rising steadily until january 25th of this year it's stayed between 24 and 26. what do you think will happen with the stock in the future? >> which one of you dogs is named intel? they all looked up and they all answered to intel. here's the deal with intel. i think it is one of the most undervalued companies. why? because i don't think people are give credit for its initiatives when it comes to wireless. i think intel with a 3% yield and a fantastic balance sheet is a terrific buy. i want to own it, and i would s

hearing to the lawyers on each side will be reported immediately, and you'll see health care starts and pharma stocks rising and falling depending on the conversation in that room. that will take place the end of march. >> i think it's very, very close. if you look at it on an ideological basis, best guess is 5-4 in favor of overturning that mandate and overturning a key principle of obama care. >> and the oral arguments are not one hour, as they normally are, they're five-hour oral arguments. you'll have plenty of opportunity as todd said to -- >> the men in black and women in black are coming out. it can be scary for a lot of people. >> good to see you both. thank you, todd. see you in a few minutes. >> thank you, todd. thank you, david. >> news breaking right now. speaking of jeremy lin, he may be responsible for breaking of a deadlock here. >> you might call it that. looks like according to "the new york times," reporting that msg and time warner has settled their dispute. as millions of subscribers know, it's been since january #st that they've not had the msg channel where they can get t

think of a pharma company when it loses and when lipitor is coming off patent, investors understand pricing's to go down, margins are going to go down and the stock reflects that. and everybody understands that. it's the law of capitalism. but here at green mountain spinning this story that somehow these enormously profitable business for them when it comes off patent is sudden they're not going to see a big decline in market share and pricing and so forth and that's just silly. >> one comment quickly and then i have to go on salesforce. >> sure. this is sort of i would say similar to lululemon in that it's a company that's doing well, growing rapidly, but the valuation's just gotten extreme. it's got $17.7 billion market cap and trading at north of eight times sales. just too much optimism built into the stock. >> 30% year-to-date. final trade when we come back. [ leanne ] appliance park has been here since the early 50s. my dad and grandfather spent their whole careers here. [ charlie ] we're the heartbeat of this place, the people on the line. we take pride in what we do. when that refrige

in pack, i wonder if they can go the way of the big pharma stocks.like merck and pfizer, both 3.8% long-term growth rates and now they're multiples have shrunk in the high single digits and many stocks in the group have no growth at all and they have the high dividend, and when i look at the presentations they got from the annual dog and pony show in boca, i think we'll have to start challenging our a slumpings about what we should pay for these stocks. 15 and 16 times earnings doesn't seem quite right. they're just too cheap, versus the stock competition with fresh innovation kebeing the norm. you need a catalyst leak a new acquisition that moves the needle and think kellogg, and think b & g foods and the dividend booster who we heard yesterday. if you want to sleep soundly tonight, maybe it's time to think about earning intel or microsoft. it offers a higher reward at a lower risk to earnings. stick with cramer. >>> it's midnight in michigan for mitt. eric cantor visits with a new jobs plan and jimmy rogers and the panel talk dow 13,000. [ male ann

pharma's holding up pretty well. >> bob, thank you.he head of the house budget committee is taking aim at ben bernanke today, saying the fed policies would do more harm than good given the low level of interest rates. during bernanke's testimony today on the state of the economy, republican congressman paul ryan said the fed's moves would risk higher growth. he talks more about that. plus we get reaction to the latest outlook for the budget office's expectations on the economy. congressman, always wonderful to have you on the program. >> good afternoon. >> let me get your take on where we are in the recovery first off. because we know that the cbo confirmed yesterday that it's projecting economic growth to remain sluggish. how do you characterize things today? >> look at the last time we had a recession like this in '82, the first year after that recession we grew. the fed was way off on its growth projections, now downw d downward. the point i was trying to make with chairman bernanke is i'm glad that he's adding more transparency to

what impact will this have on big pharma and the future of the drug industry.leveland clinic will be here to explain. ♪ [ kareem ] i was fascinated by balsa wood airplanes since i was a kid. [ mike ] i always wondered how did an airplane get in the air. at ge aviation, we build jet engines. we lift people up off the ground to 35 thousand feet. these engines are built by hand with very precise assembly techniques. [ mike ] it's gonna fly people around the world. safely and better than it's ever done before. it would be a real treat to hear this monster fire up. [ jaronda ] i think a lot of people, when they look at a jet engine, they see a big hunk of metal. but when i look at it, i see seth, mark, tom, and people like that who work on engines every day. [ tom ] i would love to see this thing fly. [ kareem ] it's a dream, honestly. there it is. oh, wow. that's so cool! yeah, that was awesome! [ cheering ] [ tom ] i wanna see that again. ♪ >>> we've got the arrows all pointed to the down side. coca-cola, jpmorgan and home depot are the biggest winners. and win re

look at pharma. two companies, savvy ceo leaving to take over at den dreen. quick silver in a bit of quick sand. downgraded from buy to underperform. that's a big swing at bank of america, merrill lynch. price target slashed from 12 to 3. this is more damage from the collapse of the prices in natural gas. tyler, sorry, took four stocks in 40 seconds. >> that's okay, baby. and den dree on, social gaming may be one thing pushing facebook's ipo but coming at the expense of traditional gamers in some instances. electronic arts going to report fourth quarter numbers after the bell today. and turn to edward williams, managing director with bmo markets. good to have you with us. >> thank you for having me. >> give us some sort of guidelines here. what do you expect these numbers to show? what would surprise you positively? what would alarm you negatively? >> i think, you know, what we're looking for is revenues around $1.6 billion. earnings per share to come in somewhere in the mid-90 cent level. but the key number to look for, the key thing to focus on is what happ

gilliad sciences, topic of conversation on the call will certainly be $11 billion acquisition of pharma asset and when they plan to launch the hepatitis c drug. >>> lawmakers holding hearings today on capitol hill about the collapse of mf global. this time they're focusing on the role of risk managers at the business. kayla tausche has the latest. >> simon, at this moment we have the reps from moody's and s&p testifying. they're in the thick of it. after this morning mf's former risk chiefs were grilled on the missing money. their answer they don't know and had nothing to do with that. but there was some familiar territory like whether mf global purposely placed a conservative risk manager in michael roseman with a more lenient one in michael stockman in order to make the bigger trades. >> it almost looks like they took mr. roseman out and replaced mr. roseman with the yes-man. does it look that way to you guys? mr. roseman, would you comment at all you gave them information they didn't like and replaced you and put someone in that gave them information that they liked? >> i would say s

>> we like big pharma and they have drugs on the pipe. i'm not worried about eli lilly at all.hat's hot and what's not? what's working and what's not? there's a dichotomy in the market in 2012. dividends versus buybacks, i know i want to be on team dividend. you should, too. "mad money" will be right back. >>> coming up, golden opportunity? could what happened today make or break the market for the next six months? cramer is checking the technicals to find out, on an all new off the charts. later, indiscretionary spending the rich get richer and they love to show off. cramer says if you can't beat them, join them and find companies behind the toys for the wealthy. hold on tight for a stock that can take you on a wild ride. plus, down, but not out. while january's been one of the best for the markets in over a decade, dominion resources has been running on fumes, down about 6%, but could exporting nat gas fuel the stock higher? cramer drills down with the company's ceo all coming up on "mad money." >>> miss out on some "mad money?" get your mad money text alert today. text mm to

and tonight i think i might have found a good one for you in allergan, agn, the cramer fave pharma andthetics play. they almost always sell off their reports even though they tend to be pretty darn good. this morning, allergan delivered a solid quarter posting inline sales and earnings, but hammered falling $2.45, 3%, because the company's guidance was widely considered disappointing and people worried about botox sales. i think this is a good opportunity to start a position in allergan. this company spends a ton of money on research and development and those investments are paying off. as right now they've got over 30 products in late-stage development. don't just take it from me. let's check in with allergan's excellent chairman and ceo to dig deeper into the quarter and find out what comes next. welcome back to "mad money." >> good to be with you, jim, thanks for the words. >> david, some people in this quarter were critical who had not been critical before saying they expected botox sales to be better, particularly because you got some of the migraine business using botox to stop m

is enough testing being done prior to being sold at the local pharma pharmacy? a very hot topic. >> certainly is. and whether companies like that are very snugly with the fda and therefore these things get approved quicker. i don't know, but people have talked about that's one theory. thank you so much, seema. >> let's get back to the markets, right. we got to thinking about dow theory where the transports leadist and there's a great piece on cnbc.com if you ever want to check it out it's among the most read on the site about what the transports are telling us. and what they may be saying despite this nice run, could there be a slowdown ahead? let's bring in chief technical strategist at s&p capital iq. what are the transports telling us and you about the overall market right now? >> well, i've been looking for a top in the s&p 500 between about 1360 and 1380. we did go to new highs on the dow jones industrials but we did not on the dow jones transports. at the recent high the transports were still about 4% from their highs that we saw last year. so we have a no

pharma, after getting picked up as a buy at citi, up 4.5%. huge volume on community health.beat on the top line and received a favorable letter from a pension investment group. that has the shares soars 15%. health stream is up 31%. internet learning and research company, strong earnings. my favorite name of the day is almost family. actually it's pretty serious company, 16.5% to the upside. on the down side, lumber liquidators, i won't make a joke, because they definitely make a lot of money here. they did miss on earnings and divide answer was guidance is d. some of the 2011 ipos i mentioned, real estate, music and my single-letter tickers have good years. they're getting help today. zilo up 27% for the year. and pandora down 4.5% but still up 23 for the year. the headphones up 24%. and 27% for the year. back to you, mandy. >> thanks very much, brian. coming up next, we'll be right back with the closing countdown. after the bell, instant analysis, hewlett-packard's earnings will be out at the top of the hour. but first, this is how the major averages are trading as we head

. >> well, when you have joe bag donuts pharma bankrupt in two years and still own a bank stock thatur kid through college, then we can talk about long-term. >> brian, my advice to you, mary, when you fight it out, talk about notre dame. >> who won, brian? >> notre dame football the last two years, mary. >> who won this? >> we got to go. you need to sit down over some chowder and talk this over. >> he's going to declare a winner. >> you've got to declare a winner, brian. >> you need to pick a winner. >> pick the winners then. you guys do it. >> you pick it. >> oh, i got to do it? giants. giants are going to win. >> thank you. >> and according to my super bowl pool -- >> this is about stocks, brian. boston stocks win, patriots win. >> it's over. we win. >> i need a safety. >> i'm throwing the flag. >> it's over. declared the winner. >> they're getting fired up. >> that's it. >> all right. guys, thank you very much. wow. epic. brian shactman taking on the new york side. he's an ex-pat. both the giants and pats have each won three super bowls. so we're going to look at the market and ho

there's no doubt pharma is going to continue to acquire biotech companies but they're going to buy biggerpanies where it can move the needle in terms of products. so just be very cautious on the space. >> just to echo that. this is the closest thing in the public markets that you're going to get to venture capital. people do basically know you're going to do ten stocks. one of them is going to be bought. one of them might do well, eight of them are probably going to dwindle. that's exactly the way you have to look at it. >> it's a basket approach. you can't pick one, no matter how good it sounds, and say i'm buying that one. >> take a look at apple. it's above $503. there it is. $503.50 up fractionally. >> 23 minutes really didn't mention apple very much. >> apple watch on the screen. like a little apple graphic with numbers. >> obviously you weren't watching the last couple of days zach. that was happening before it hit 500. great thought. >> an apple. an actually little apple. >> coming up we're going to talk to an analyst about why he's raising his estimates today. next the s&p up abou

key drug this past july difisid which is co-marketing with a very hot stock, cubis pharma.rong. i think there could be up side based on label expansion. the stock hasn't run too much. and i think it's an interesting speculative play on treating hospital-based infections, which are a real problem in the health care biz. but it's for speculation only. be sure to use limit orders, not market orders. on january 25th, irving in california asked me about massimo. not the jeans company. mosi. a leading maker of pulse ok simm tri devices. which are used in emergency room departments. with new product launches, an uptick in surgeries and a reasonable valuation 2012 could be a good year for this stock. however, this is a distinctly second half story. right? the first half of the year is likely to be challenging for massimo. so i wouldn't buy it until we get a pullback since there's absolutely no rush. for now the thing to do, how about nothing? then on january 26th richard in virginia called me about a stock i'm asked about a lot of times on the street. ziopharm oncology. teency tiny

. >>> moving to the pharma beat, we have seema mody talking jane j. recalls of iconic brand tylenol battered reputation and facing intense generic competition and stock gone nowhere over the past five years. can j & j's new ceo turn it around? talk about a long and winding road for them. >> it surely has been a winding road for the company. first priority for the company is to fix some of these glaring problems. they're dealing with manufacturing errors, ongoing supply chain issues and that all led to a series of recalls as you can see right here. now i've been speaking to analyst who is have covered this company since the news broke. overall a positive reaction to welden stepping down. and most thinking alex is up to the challenge. he's actually the 411 on the new face of j & j. he's a former army captain joined as a sales rep in '88. switched over in 2004 to head the north american pharmaceutical business and then returned to j & j. the question is will his top priority be? one can only speculate, but first it's pretty obvious no more recalls. fix t

the pharma trades coming in right now with crude settling down about 1%.'s get a check on all the latest action from the floor of the new york stock exchange. joining us matt cheslock. we pierced the 13,000 mark several times. are we able to convincingly hold above it by the close? what's going to happen this week? what are the trading levels we were looking at? >> i wish i knew because i would make a good bet on it. people have been very optimistic about going forward here. this has beaten wildest expectations this move that began since the beginning of the year. so i would anticipate us being stuck at 13,000 for a while. i would imagine 100-point pullback in the dow would probably be met with buying. but a 500-point loss may be met with some selling. that's what people will watch for to see if this selloff does occur how strong it is. >> you say there's a lot of optimism. i feel a lot of things people are optimistic about is already priced in. what will take us to the next level, matt? >> i would think oil coming in below $100 would be one catalyst. the